Tengshengbo Medicine-B (02137): Published results of the ENSURE II study in "Nature Medicine".

Infortmation from the Wise Finance APP, Tencent Biopharmaceuticals-B (02137) announced that the results of the ENSURE II study have been published in the peer-reviewed journal "Nature Medicine". The study evaluated the effectiveness and safety of the siRNA drug elebsiran in combination with pegylated interferon alpha (PEG-IFN) treatment regimen, with PEG-IFN monotherapy as the control group. In addition, the study also explored the potential role of the hepatitis B virus (HBV) therapeutic vaccine BRII-179 in identifying immune response patients and increasing the clearance rate of hepatitis B surface antigen (HBsAg).